a developer of drugs to treat inflammatory diseases and cancer
Industry Biotechnology
A.I.dvisor indicates that over the last year, GLYC has been closely correlated with LYRA. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLYC jumps, then LYRA could also see price increases.
Ticker / NAME | Correlation To GLYC | 1D Price Change % | ||
---|---|---|---|---|
GLYC | 100% | -0.65% | ||
LYRA - GLYC | 76% Closely correlated | -8.95% | ||
ROQAF - GLYC | 72% Closely correlated | N/A | ||
IONS - GLYC | 35% Loosely correlated | -1.46% | ||
ALLO - GLYC | 33% Loosely correlated | -9.56% | ||
ELVN - GLYC | 31% Poorly correlated | -3.41% | ||
More |
Ticker / NAME | Correlation To GLYC | 1D Price Change % |
---|---|---|
GLYC | 100% | -0.65% |
GLYC (2 stocks) | 92% Closely correlated | +1.38% |
cancer (82 stocks) | 11% Poorly correlated | -2.35% |
drugs (254 stocks) | 10% Poorly correlated | -1.67% |
inflammation (11 stocks) | 6% Poorly correlated | -2.42% |
biotechnology (238 stocks) | 4% Poorly correlated | -1.76% |